Full-Time
Clinical trial endpoint technology solutions provider
No salary listed
Senior
Bengaluru, Karnataka, India
In Person
Clario specializes in technologies for clinical trials, focusing on solutions that improve drug development by enhancing efficacy, ensuring safety, and boosting patient quality of life. Their products include advanced software, connected devices, and artificial intelligence tools that support various therapeutic areas such as cardiac safety and medical imaging. Clario's platform is adaptable for different trial types, including site-based, hybrid, and fully decentralized trials, making it flexible for sponsors and research organizations. What sets Clario apart from competitors is its extensive experience, having participated in over 26,000 clinical trials across more than 100 countries, and its commitment to simplifying the clinical trial process with integrated training and 24/7 support. The company's goal is to empower patient choice, promote diversity in clinical trials, and enhance health equity by prioritizing the well-being of participants.
Company Size
5,001-10,000
Company Stage
Growth Equity (Venture Capital)
Total Funding
$29.9M
Headquarters
London, United Kingdom
Founded
1972
Help us improve and share your feedback! Did you find this helpful?
Competitive and equitable total rewards package
Physical, mental and financial health and wellness
Flexible working approach
NeuroRx founder and CEO Douglas Arnold, M.D., is also joining Clario as a senior scientific advisor, Clario announced in a March 17 release.
Clario, a Philadelphia-based provider of endpoint data solutions to the clinical trial industry, has acquired NeuroRx, a Montreal-based provider of imaging analysis on multiple sclerosis.
Clario, a leader in endpoint data solutions for clinical trials, has acquired NeuroRx, an imaging analysis expert in multiple sclerosis. This acquisition enhances Clario's neuroscience capabilities. NeuroRx's founder, Douglas Arnold, M.D., will join Clario as Senior Scientific Advisor. Clario also plans to acquire WCG’s eCOA business, further strengthening its neuroscience expertise.
Acquisition of WCG's electronic clinical outcome assessments (eCOA) business will expand Clario's scientific expertise and offerings in neurosciencePHILADELPHIA, March 10, 2025 /PRNewswire/ -- Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced they have entered into a definitive agreement to acquire the eCOA business of WCG, a leader in providing solutions that measurably improve and accelerate clinical research. Electronic clinical outcomes assessments (eCOA), in addition to paper assessments, are used to evaluate the safety and efficacy of new drugs by measuring how a clinical trial participant feels or functions. WCG's eCOA operations offer robust, full-service clinical expertise and specialized functionality, particularly in neurology, psychiatry, neuropathic pain, and rare diseases
PHILADELPHIA - October 10, 2024 - Clario, a leading provider of endpoint data solutions to the clinical trials industry, is excited to announce a strategic partnership with PathAI, a leader in AI-powered digital pathology solutions aimed at improving diagnostic accuracy and efficiency.